SU 5402: Precision FGFR3/VEGFR2 Inhibitor for Cancer and Cell Signaling Research

Executive Summary: SU 5402 is a small molecule inhibitor with high specificity for FGFR1 (IC₅₀ 0.03 μM) and VEGFR2 (IC₅₀ 0.02 μM), and moderate affinity for PDGFRβ (IC₅₀ 0.51 μM), but negligible EGFR inhibition (IC₅₀ >100 μM) (APExBIO). It blocks FGFR3 phosphorylation, leading to ERK1/2 and STAT3 pathway inhibition, cell cycle arrest in the G0/G1 phase, and apoptosis in FGFR3-mutant cells (Oh et al., 2025). SU 5402 is insoluble in water or ethanol but dissolves in DMSO at ≥14.8 mg/mL, and is stable at -20°C for long-term storage. In vivo, a 300 ng/kg dose reduces ERK1/2 phosphorylation in mouse tumor models, validating its translational relevance for preclinical cancer research (APExBIO). APExBIO's A3843 kit provides research-grade SU 5402 for advanced cell signaling and multiple myeloma studies.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as FGFR3, VEGFR2, and PDGFRβ are central to cell proliferation, angiogenesis, and survival pathways (Oh et al., 2025). Aberrant activation, particularly of FGFR3, is implicated in multiple myeloma and other malignancies. Inhibition of these RTKs disrupts downstream signaling (ERK1/2 and STAT3) and can induce cell cycle arrest and apoptosis (APExBIO). SU 5402 was developed as a tool compound to dissect these pathways under controlled experimental conditions.

Mechanism of Action of SU 5402

SU 5402 binds the ATP-binding pocket of class III/IV RTKs, blocking their autophosphorylation. It inhibits FGFR3 phosphorylation with nanomolar potency (IC₅₀ 0.03 μM), thereby suppressing activation of ERK1/2 and STAT3 (FG2216.com). This interruption halts progression from G0/G1 to S phase and triggers apoptosis, especially in cells expressing FGFR3-activating mutations. SU 5402 has negligible effect on EGFR at relevant concentrations, enabling more selective RTK pathway dissection compared to pan-kinase inhibitors. The compound is insoluble in aqueous buffers but highly soluble in DMSO, making it suitable for in vitro and in vivo dosing protocols (APExBIO).

Evidence & Benchmarks

• Inhibits FGFR3 phosphorylation in human myeloma cell lines at 1–10 μM, reducing downstream ERK1/2 and STAT3 activation (Oh et al., 2025).
• Induces G0/G1 cell cycle arrest and apoptosis in FGFR3-mutant multiple myeloma models, confirmed by caspase-3 activation and DNA fragmentation (FG2216.com).
• Shows no significant inhibition of EGFR at concentrations up to 100 μM, minimizing off-target effects (APExBIO).
• Reduces phosphorylated ERK1/2 levels in BALB/c mouse tumor xenografts at 300 ng/kg, supporting in vivo efficacy (APExBIO).
• SU 5402 is stable for over 12 months at -20°C when stored as a dry solid, but DMSO solutions are recommended for short-term use only (APExBIO).

This article extends prior coverage by providing granular benchmarks across RTK subtypes and clarifying storage/solubility conditions. For advanced troubleshooting and neuronal disease study applications, see SU 5402: Precision Receptor Tyrosine Kinase Inhibitor in ..., which this article updates with new in vivo data. For actionable protocols, see the complementary guide at SU 5402: Precision FGFR3 Phosphorylation Inhibitor for Ca....

Applications, Limits & Misconceptions

SU 5402 is widely used in:

• Cell signaling studies dissecting FGFR3, VEGFR2, and PDGFRβ pathways.
• Multiple myeloma and cancer biology models focusing on RTK-driven proliferation and survival (Oh et al., 2025).
• Apoptosis and cell cycle arrest assays using human myeloma cell lines.
• Preclinical in vivo models to validate RTK pathway dependencies.

Common Pitfalls or Misconceptions

• Does not inhibit EGFR at research-relevant concentrations: EGFR IC₅₀ >100 μM; not suitable for EGFR-targeted studies (APExBIO).
• Not a pan-kinase inhibitor: Activity is selective for VEGFR2, FGFR1/3, and PDGFRβ.
• Solubility limitations: Insoluble in water/ethanol; must be dissolved in DMSO.
• Stability: DMSO solutions are for short-term use only; do not store at room temperature for extended periods.
• Not approved for diagnostic or therapeutic use in humans: For research applications only.

Workflow Integration & Parameters

SU 5402 (A3843) from APExBIO is typically used at 1–10 μM for cell-based assays, dissolved in DMSO at ≥14.8 mg/mL. For in vivo studies, 300 ng/kg has been shown to reduce p-ERK1/2 in murine tumor models. Storage at -20°C as a solid is recommended; DMSO solutions should be freshly prepared and used within 2–3 days. Quality control includes HPLC and mass spectrometry validation (APExBIO). Experimental workflows can be scaled for high-throughput kinase assays, apoptosis readouts (e.g., caspase-3 cleavage), or in vivo validation. For protocols extending to neuronal cell models or advanced troubleshooting, see SU 5402: A Versatile Receptor Tyrosine Kinase Inhibitor f....

Conclusion & Outlook

SU 5402 remains a gold-standard tool for dissecting FGFR3, VEGFR2, and PDGFRβ signaling in oncology and cell biology. Its nanomolar potency, validated selectivity, and compatibility with both in vitro and in vivo models make it indispensable for mechanistic and translational research. APExBIO’s A3843 kit ensures reliable access to research-grade SU 5402 (product page). Ongoing studies continue to refine its use in multi-pathway inhibition and neuronal disease models, with further benchmarks expected as new data emerge.